Eli Lilly Reports Temporary Shortage of Humalog and Insulin Lispro Injection
By Physician’s Briefing Staff HealthDay Reporter
MONDAY, March 25, 2024 -- Eli Lilly & Co. announced on Friday a temporary shortage of two of its insulin products.
"The 10 mL vials of Humalog and Insulin Lispro Injection are or will be temporarily out of stock at wholesalers and some pharmacies through the beginning of April," Lilly said in a recent statement. The company added it is continuing to make the 10-mL vials and "will ship them as soon as we can." However, in the meantime, patients with diabetes may need to consult with their doctors "to discuss switching to the same insulin in a prefilled pen or other insulin treatment options."
Switching to another product may be more easily said than done, noted patient advocate Laura Marston. She has type 1 diabetes and uses Humalog. Marston told CNN that she uses the vials in her insulin pump. Her insurance only covers the vials through a prior authorization process that may be tough to get around. "If Lilly doesn't fix this fast, I actually don't know what I'm going to do," Marston said.
Lilly said it is offering customers without insurance a coupon program offering insulin for $35. "We recognize that any supply challenge may cause a disruption in people's treatment regimens, and we are moving with urgency to address it," its statement said. "Patients who need insulin immediately and cannot access their health care provider for an alternative treatment option should seek emergency care."
Lilly spokesman Tarsis Lopez told CNN that the "dynamic nature of insulin supply and demand, coupled with a brief delay in manufacturing, led to the temporary supply constraint."
CNN Article
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
SGLT2 Inhibitors Improve Outcomes in Patients With Diabetes Plus Kidney Disease
THURSDAY, May 2, 2024 -- Use of sodium–glucose cotransporter-2 inhibitors (SGLT2is) is associated with a substantially lower risk for dialysis and cardiovascular disease in...
American College of Physicians, April 18-20
The annual meeting of the American College of Physicians (Internal Medicine Meeting) was held from April 18 to 20 in Boston and was attended by internists, adult medicine...
Intensive HTN Treatment Cuts Early T2D Diagnosis-Linked CVD Event Risk
MONDAY, April 29, 2024 -- More intensive hypertensive therapy significantly reduces the excess risk for cardiovascular disease (CVD) events associated with earlier hypertension...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.